TY - JOUR
T1 - NEFROPATÍA POR IgA: LA PRINCIPAL GLOMERULONEFRITIS PRIMARIA DEL MUNDO
AU - Montoya, Andrés Eduardo Toro
AU - Restrepo, Cristian Camilo Benítez
AU - Sánchez, Lina María Martínez
PY - 2009
Y1 - 2009
N2 - IgA nephropathy is a mesangial proliferative glomerular disease, mediated by immune complexes, due to the deposition of type A globulin; it is regarded as the first cause of primary glomerulonephritis in the world. It is estimated that it affects 1.3% of the population. Its incidence is variable, being estimated in Asia in 29%, in Australia 12%, in Europe 10% and in the United States 10-15%. It is more frequent in men than in women in a relation of 6:1 to 10:1 and it occurs mainly between 16 to 40 years of age. It is a glomerulopathy which has a variable clinical course and which can lead to end stage renal disease, with the social and financial consequences that it brings. Nowadays, there is more knowledge about the evolution, risk factors for the development of end stage renal insufficiency and new therapeutic alternatives; that is why it is important to establish this patients¿ clinical and histopathological characteristics to determine the behavior of the population with this disease and define the most appropriate treatment, individually and collectively.
AB - IgA nephropathy is a mesangial proliferative glomerular disease, mediated by immune complexes, due to the deposition of type A globulin; it is regarded as the first cause of primary glomerulonephritis in the world. It is estimated that it affects 1.3% of the population. Its incidence is variable, being estimated in Asia in 29%, in Australia 12%, in Europe 10% and in the United States 10-15%. It is more frequent in men than in women in a relation of 6:1 to 10:1 and it occurs mainly between 16 to 40 years of age. It is a glomerulopathy which has a variable clinical course and which can lead to end stage renal disease, with the social and financial consequences that it brings. Nowadays, there is more knowledge about the evolution, risk factors for the development of end stage renal insufficiency and new therapeutic alternatives; that is why it is important to establish this patients¿ clinical and histopathological characteristics to determine the behavior of the population with this disease and define the most appropriate treatment, individually and collectively.
UR - http://www.redalyc.org/articulo.oa?id=159013067006
M3 - Artículo en revista científica indexada
JO - Medicina U.P.B.
JF - Medicina U.P.B.
ER -